OBJECTIVE： To systematically evaluate the therapeutic efficacy and safety of perospirone versus  risperidone in the treatment of schizophrenia， and to provide evidence-based reference for clinical treatment. METHODS： Retrieved from Wanfang database， VIP， CJFD， CBM and PubMed， randomized controlled trials （RCTs） of perospirone（trial group） vs. risperidone （control group） in the treatment of schizophrenia were collected. After data extraction and quality evaluation of included studies according to modified Jadad evaluation criteria， Meta-analysis of response indexes was performed by using Rev Man 5.0 statistical software. RESULTS： A total of 12 RCTs were included， involving 1 050 patients. Results of Meta-analysis showed， the cure rate of 2 groups had no statistical significance [OR＝0.99，95％CI（075，1.30），P＝0.93]. The incidences of extrapyramidal reactions [OR＝0.63，95％CI（0.43，0.92），P＝0.02]， the incidences of prolactin levels increasing [OR＝0.23，95％CI（0.14，0.38），P＜0.001] and the incidences of weight gain [OR＝0.23，95％CI（0.13，0.39），P＜0.001] in control group were significantly higher than trial group， with statistical significance （P＜0.05）. CONCLUSIONS： The therapeutic efficacy of perospirone and risperidone is similar in the treatment of schizophrenia， but the safety of perospirone is better than that of risperidone.